Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Gallic acid, a common dietary phenolic protects against high fat diet induced DNA damage.

Setayesh T, Nersesyan A, Mišík M, Noorizadeh R, Haslinger E, Javaheri T, Lang E, Grusch M, Huber W, Haslberger A, Knasmüller S.

Eur J Nutr. 2018 Jul 23. doi: 10.1007/s00394-018-1782-2. [Epub ahead of print]

PMID:
30039436
2.

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.

Molnár E, Rittler D, Baranyi M, Grusch M, Berger W, Döme B, Tóvári J, Aigner C, Tímár J, Garay T, Hegedűs B.

BMC Cancer. 2018 May 8;18(1):542. doi: 10.1186/s12885-018-4455-x.

3.

Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo.

Laszlo V, Valko Z, Kovacs I, Ozsvar J, Hoda MA, Klikovits T, Lakatos D, Czirok A, Garay T, Stiglbauer A, Helbich TH, Gröger M, Tovari J, Klepetko W, Pirker C, Grusch M, Berger W, Hilberg F, Hegedus B, Dome B.

Clin Cancer Res. 2018 Aug 1;24(15):3729-3740. doi: 10.1158/1078-0432.CCR-17-1507. Epub 2018 May 3.

PMID:
29724868
4.

Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis.

Groza D, Gehrig S, Kudela P, Holcmann M, Pirker C, Dinhof C, Schueffl HH, Sramko M, Hoebart J, Alioglu F, Grusch M, Ogris M, Lubitz W, Keppler BK, Pashkunova-Martic I, Kowol CR, Sibilia M, Berger W, Heffeter P.

Oncoimmunology. 2018 Feb 16;7(5):e1424676. doi: 10.1080/2162402X.2018.1424676. eCollection 2018.

PMID:
29721389
5.

Epigenetic Biomarkers in Cancer.

Cheng YY, Jin HC, Chan MWY, Chu WK, Grusch M.

Dis Markers. 2018 Feb 20;2018:4987103. doi: 10.1155/2018/4987103. eCollection 2018. No abstract available.

6.

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.

Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, Lin R, Kirschner MB, Mohr T, Brcic L, Marian B, Holzmann K, Grasl-Kraupp B, Krupitza G, Laszlo V, Klikovits T, Dome B, Hegedus B, Garay T, Reid G, van Zandwijk N, Klepetko W, Berger W, Grusch M, Hoda MA.

Carcinogenesis. 2018 Apr 5;39(4):534-545. doi: 10.1093/carcin/bgy018.

PMID:
29635378
7.

Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma.

Klikovits T, Stockhammer P, Laszlo V, Dong Y, Hoda MA, Ghanim B, Opitz I, Frauenfelder T, Nguyen-Kim TDL, Weder W, Berger W, Grusch M, Aigner C, Klepetko W, Dome B, Renyi-Vamos F, Oehler R, Hegedus B.

Sci Rep. 2017 Nov 28;7(1):16456. doi: 10.1038/s41598-017-16551-7.

8.

FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo.

Ghassemi S, Vejdovszky K, Sahin E, Ratzinger L, Schelch K, Mohr T, Peter-Vörösmarty B, Brankovic J, Lackner A, Leopoldi A, Meindl D, Pirker C, Hegedus B, Marian B, Holzmann K, Grasl-Kraupp B, Heffeter P, Berger W, Grusch M.

Oncotarget. 2017 Sep 23;8(50):87750-87762. doi: 10.18632/oncotarget.21184. eCollection 2017 Oct 20.

9.

A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma.

Schelch K, Kirschner MB, Williams M, Cheng YY, van Zandwijk N, Grusch M, Reid G.

Mol Oncol. 2018 Jan;12(1):58-73. doi: 10.1002/1878-0261.12150. Epub 2017 Nov 18.

10.

DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer.

Leygo C, Williams M, Jin HC, Chan MWY, Chu WK, Grusch M, Cheng YY.

Dis Markers. 2017;2017:3726595. doi: 10.1155/2017/3726595. Epub 2017 Sep 5. Review.

11.

Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer.

Englinger B, Kallus S, Senkiv J, Heilos D, Gabler L, van Schoonhoven S, Terenzi A, Moser P, Pirker C, Timelthaler G, Jäger W, Kowol CR, Heffeter P, Grusch M, Berger W.

J Exp Clin Cancer Res. 2017 Sep 7;36(1):122. doi: 10.1186/s13046-017-0592-3.

12.

Long-term exposure of immortalized keratinocytes to arsenic induces EMT, impairs differentiation in organotypic skin models and mimics aspects of human skin derangements.

Weinmuellner R, Kryeziu K, Zbiral B, Tav K, Schoenhacker-Alte B, Groza D, Wimmer L, Schosserer M, Nagelreiter F, Rösinger S, Mildner M, Tschachler E, Grusch M, Grillari J, Heffeter P.

Arch Toxicol. 2018 Jan;92(1):181-194. doi: 10.1007/s00204-017-2034-6. Epub 2017 Aug 3.

13.

Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca2+ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK.

Hegedüs L, Padányi R, Molnár J, Pászty K, Varga K, Kenessey I, Sárközy E, Wolf M, Grusch M, Hegyi Z, Homolya L, Aigner C, Garay T, Hegedüs B, Tímár J, Kállay E, Enyedi Á.

Front Oncol. 2017 May 24;7:95. doi: 10.3389/fonc.2017.00095. eCollection 2017.

14.

Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis.

Erdem ZN, Schwarz S, Drev D, Heinzle C, Reti A, Heffeter P, Hudec X, Holzmann K, Grasl-Kraupp B, Berger W, Grusch M, Marian B.

Transl Oncol. 2017 Jun;10(3):332-339. doi: 10.1016/j.tranon.2017.02.004. Epub 2017 Mar 22.

15.

Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance.

Englinger B, Mair M, Miklos W, Pirker C, Mohr T, van Schoonhoven S, Lötsch D, Körner W, Ferk F, Knasmüller S, Heffeter P, Keppler BK, Grusch M, Berger W.

Br J Cancer. 2017 Feb 14;116(4):489-500. doi: 10.1038/bjc.2016.449. Epub 2017 Jan 17.

16.

The plasma membrane Ca2+ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells.

Hegedũs L, Garay T, Molnár E, Varga K, Bilecz Á, Török S, Padányi R, Pászty K, Wolf M, Grusch M, Kállay E, Döme B, Berger W, Hegedũs B, Enyedi A.

Int J Cancer. 2017 Jun 15;140(12):2758-2770. doi: 10.1002/ijc.30503. Epub 2016 Nov 17.

17.

Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.

Ahmed MA, Selzer E, Dörr W, Jomrich G, Harpain F, Silberhumer GR, Müllauer L, Holzmann K, Grasl-Kraupp B, Grusch M, Berger W, Marian B.

Oncotarget. 2016 Oct 25;7(43):69976-69990. doi: 10.18632/oncotarget.12099.

18.

Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.

Hoda MA, Pirker C, Dong Y, Schelch K, Heffeter P, Kryeziu K, van Schoonhoven S, Klikovits T, Laszlo V, Rozsas A, Ozsvar J, Klepetko W, Döme B, Grusch M, Hegedüs B, Berger W.

Mol Cancer Ther. 2016 Oct;15(10):2357-2369. Epub 2016 Aug 10.

19.

Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.

Englinger B, Lötsch D, Pirker C, Mohr T, van Schoonhoven S, Boidol B, Lardeau CH, Spitzwieser M, Szabó P, Heffeter P, Lang I, Cichna-Markl M, Grasl-Kraupp B, Marian B, Grusch M, Kubicek S, Szakács G, Berger W.

Oncotarget. 2016 Aug 2;7(31):50161-50179. doi: 10.18632/oncotarget.10324.

20.

Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.

Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, Stockhammer P, Ozsvar J, Jakopovic M, Samarzija M, Brcic L, Bendek M, Szirtes I, Reid G, Kirschner MB, Kao SC, Opitz I, Weder W, Frauenfelder T, Nguyen-Kim TD, Aigner C, Klepetko W, van Zandwijk N, Berger W, Dome B, Grusch M, Hegedus B.

Eur J Cancer. 2016 Aug;63:64-73. doi: 10.1016/j.ejca.2016.04.018. Epub 2016 Jun 8.

PMID:
27288871
21.

High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.

Hoda MA, Rozsas A, Lang E, Klikovits T, Lohinai Z, Torok S, Berta J, Bendek M, Berger W, Hegedus B, Klepetko W, Renyi-Vamos F, Grusch M, Dome B, Laszlo V.

Oncotarget. 2016 Mar 22;7(12):13388-99. doi: 10.18632/oncotarget.7796.

22.

Light-assisted small-molecule screening against protein kinases.

Inglés-Prieto Á, Reichhart E, Muellner MK, Nowak M, Nijman SM, Grusch M, Janovjak H.

Nat Chem Biol. 2015 Dec;11(12):952-4. doi: 10.1038/nchembio.1933. Epub 2015 Oct 12.

23.

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.

Kirschner MB, Pulford E, Hoda MA, Rozsas A, Griggs K, Cheng YY, Edelman JJ, Kao SC, Hyland R, Dong Y, László V, Klikovits T, Vallely MP, Grusch M, Hegedus B, Dome B, Klepetko W, van Zandwijk N, Klebe S, Reid G.

Br J Cancer. 2015 Sep 15;113(6):963-9. doi: 10.1038/bjc.2015.286. Epub 2015 Aug 11.

24.

Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?

Paur J, Nika L, Maier C, Moscu-Gregor A, Kostka J, Huber D, Mohr T, Heffeter P, Schrottmaier WC, Kappel S, Kandioler D, Holzmann K, Marian B, Berger W, Grusch M, Grasl-Kraupp B.

Hepatology. 2015 Dec;62(6):1767-78. doi: 10.1002/hep.28023. Epub 2015 Oct 16.

PMID:
26235436
25.

The germacranolide sesquiterpene lactone neurolenin B of the medicinal plant Neurolaena lobata (L.) R.Br. ex Cass inhibits NPM/ALK-driven cell expansion and NF-κB-driven tumour intravasation.

Unger C, Kiss I, Vasas A, Lajter I, Kramer N, Atanasov AG, Nguyen CH, Chatuphonprasert W, Brenner S, Krieger S, McKinnon R, Peschel A, Kain R, Saiko P, Szekeres T, Kenner L, Hassler MR, Diaz R, Frisch R, Dirsch VM, Jäger W, de Martin R, Bochkov VN, Passreiter CM, Peter-Vörösmarty B, Mader RM, Grusch M, Dolznig H, Kopp B, Zupko I, Hohmann J, Krupitza G.

Phytomedicine. 2015 Aug 15;22(9):862-74. doi: 10.1016/j.phymed.2015.06.003. Epub 2015 Jun 26.

PMID:
26220634
26.

Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.

Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zöchbauer-Müller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B.

J Pathol. 2015 Oct;237(2):203-14. doi: 10.1002/path.4567. Epub 2015 Jul 14.

PMID:
26011651
27.

A eudesmane-type sesquiterpene isolated from Pluchea odorata (L.) Cass. combats three hallmarks of cancer cells: Unrestricted proliferation, escape from apoptosis and early metastatic outgrowth in vitro.

Blaschke M, McKinnon R, Nguyen CH, Holzner S, Zehl M, Atanasov AG, Schelch K, Krieger S, Diaz R, Frisch R, Feistel B, Jäger W, Ecker GF, Dirsch VM, Grusch M, Zupko I, Urban E, Kopp B, Krupitza G.

Mutat Res. 2015 Jul;777:79-90. doi: 10.1016/j.mrfmmm.2015.04.011. Epub 2015 May 5.

PMID:
25989051
28.

Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.

Garay T, Molnár E, Juhász É, László V, Barbai T, Dobos J, Schelch K, Pirker C, Grusch M, Berger W, Tímár J, Hegedűs B.

Pathol Oncol Res. 2015 Sep;21(4):957-68. doi: 10.1007/s12253-015-9916-9. Epub 2015 Mar 9.

PMID:
25749811
29.

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma.

Lohinai Z, Hoda MA, Fabian K, Ostoros G, Raso E, Barbai T, Timar J, Kovalszky I, Cserepes M, Rozsas A, Laszlo V, Grusch M, Berger W, Klepetko W, Moldvay J, Dome B, Hegedus B.

J Thorac Oncol. 2015 May;10(5):738-46. doi: 10.1097/JTO.0000000000000492.

30.

Epigallocatechin gallate, ellagic acid, and rosmarinic acid perturb dNTP pools and inhibit de novo DNA synthesis and proliferation of human HL-60 promyelocytic leukemia cells: Synergism with arabinofuranosylcytosine.

Saiko P, Steinmann MT, Schuster H, Graser G, Bressler S, Giessrigl B, Lackner A, Grusch M, Krupitza G, Bago-Horvath Z, Jaeger W, Fritzer-Szekeres M, Szekeres T.

Phytomedicine. 2015 Jan 15;22(1):213-22. doi: 10.1016/j.phymed.2014.11.017. Epub 2014 Dec 3.

PMID:
25636891
31.

Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.

Ghanim B, Klikovits T, Hoda MA, Lang G, Szirtes I, Setinek U, Rozsas A, Renyi-Vamos F, Laszlo V, Grusch M, Filipits M, Scheed A, Jakopovic M, Samarzija M, Brcic L, Stancic-Rokotov D, Kern I, Rozman A, Dekan G, Klepetko W, Berger W, Glasz T, Dome B, Hegedus B.

Br J Cancer. 2015 Mar 3;112(5):783-92. doi: 10.1038/bjc.2015.9. Epub 2015 Jan 29.

32.

Lobatin B inhibits NPM/ALK and NF-κB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation.

Kiss I, Unger C, Huu CN, Atanasov AG, Kramer N, Chatruphonprasert W, Brenner S, McKinnon R, Peschel A, Vasas A, Lajter I, Kain R, Saiko P, Szekeres T, Kenner L, Hassler MR, Diaz R, Frisch R, Dirsch VM, Jäger W, de Martin R, Bochkov VN, Passreiter CM, Peter-Vörösmarty B, Mader RM, Grusch M, Dolznig H, Kopp B, Zupko I, Hohmann J, Krupitza G.

Cancer Lett. 2015 Jan 28;356(2 Pt B):994-1006. doi: 10.1016/j.canlet.2014.11.019. Epub 2014 Nov 15.

PMID:
25444930
33.

The effect of organic anion-transporting polypeptides 1B1, 1B3 and 2B1 on the antitumor activity of flavopiridol in breast cancer cells.

Brenner S, Riha J, Giessrigl B, Thalhammer T, Grusch M, Krupitza G, Stieger B, Jäger W.

Int J Oncol. 2015 Jan;46(1):324-32. doi: 10.3892/ijo.2014.2731. Epub 2014 Oct 24.

PMID:
25351763
34.

Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.

Veigel D, Wagner R, Stübiger G, Wuczkowski M, Filipits M, Horvat R, Benhamú B, López-Rodríguez ML, Leisser A, Valent P, Grusch M, Hegardt FG, García J, Serra D, Auersperg N, Colomer R, Grunt TW.

Int J Cancer. 2015 May 1;136(9):2078-90. doi: 10.1002/ijc.29261. Epub 2014 Nov 3.

35.

The optogenetic promise for oncology: Episode I.

Ingles-Prieto A, Reichhart E, Schelch K, Janovjak H, Grusch M.

Mol Cell Oncol. 2014 Oct 29;1(4):e964045. doi: 10.4161/23723548.2014.964045. eCollection 2014 Oct-Dec.

36.

Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.

Schelch K, Hoda MA, Klikovits T, Münzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, Filipits M, Pirker C, Heffeter P, Selzer E, Tovari J, Torok S, Kenessey I, Holzmann K, Grasl-Kraupp B, Marian B, Klepetko W, Berger W, Hegedus B, Grusch M.

Am J Respir Crit Care Med. 2014 Oct 1;190(7):763-72. doi: 10.1164/rccm.201404-0658OC.

PMID:
25188816
37.

Activin A is anti-lymphangiogenic in a melanoma mouse model.

Heinz M, Niederleithner HL, Puujalka E, Soler-Cardona A, Grusch M, Pehamberger H, Loewe R, Petzelbauer P.

J Invest Dermatol. 2015 Jan;135(1):212-221. doi: 10.1038/jid.2014.328. Epub 2014 Aug 1.

38.

Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma.

Gauglhofer C, Paur J, Schrottmaier WC, Wingelhofer B, Huber D, Naegelen I, Pirker C, Mohr T, Heinzle C, Holzmann K, Marian B, Schulte-Hermann R, Berger W, Krupitza G, Grusch M, Grasl-Kraupp B.

Carcinogenesis. 2014 Oct;35(10):2331-8. doi: 10.1093/carcin/bgu151. Epub 2014 Jul 16.

PMID:
25031272
39.

Spatio-temporally precise activation of engineered receptor tyrosine kinases by light.

Grusch M, Schelch K, Riedler R, Reichhart E, Differ C, Berger W, Inglés-Prieto Á, Janovjak H.

EMBO J. 2014 Aug 1;33(15):1713-26. doi: 10.15252/embj.201387695. Epub 2014 Jul 1.

40.

Apelin promotes lymphangiogenesis and lymph node metastasis.

Berta J, Hoda MA, Laszlo V, Rozsas A, Garay T, Torok S, Grusch M, Berger W, Paku S, Renyi-Vamos F, Masri B, Tovari J, Groger M, Klepetko W, Hegedus B, Dome B.

Oncotarget. 2014 Jun 30;5(12):4426-37.

41.

Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.

Cserepes M, Ostoros G, Lohinai Z, Raso E, Barbai T, Timar J, Rozsas A, Moldvay J, Kovalszky I, Fabian K, Gyulai M, Ghanim B, Laszlo V, Klikovits T, Hoda MA, Grusch M, Berger W, Klepetko W, Hegedus B, Dome B.

Eur J Cancer. 2014 Jul;50(10):1819-28. doi: 10.1016/j.ejca.2014.04.001. Epub 2014 Apr 22.

42.

Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling.

Schweiger N, Hauck M, Steinhoff H, Sampl S, Reifinger M, Walter I, Kreilmeier T, Marian B, Grusch M, Berger W, Holzmann K, Kleiter M.

Mol Carcinog. 2015 Sep;54(9):841-52. doi: 10.1002/mc.22155. Epub 2014 Apr 9.

PMID:
24719266
43.

Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma.

Ghanim B, Hoda MA, Klikovits T, Winter MP, Alimohammadi A, Grusch M, Dome B, Arns M, Schenk P, Jakopovic M, Samarzija M, Brcic L, Filipits M, Laszlo V, Klepetko W, Berger W, Hegedus B.

Br J Cancer. 2014 Feb 18;110(4):984-90. doi: 10.1038/bjc.2013.815. Epub 2014 Jan 16.

44.

Inhibition of tumour spheroid-induced prometastatic intravasation gates in the lymph endothelial cell barrier by carbamazepine: drug testing in a 3D model.

Teichmann M, Kretschy N, Kopf S, Jarukamjorn K, Atanasov AG, Viola K, Giessrigl B, Saiko P, Szekeres T, Mikulits W, Dirsch VM, Huttary N, Krieger S, Jäger W, Grusch M, Dolznig H, Krupitza G.

Arch Toxicol. 2014 Mar;88(3):691-9. doi: 10.1007/s00204-013-1183-5. Epub 2013 Dec 19.

PMID:
24352538
45.

Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis.

Lötsch D, Steiner E, Holzmann K, Spiegl-Kreinecker S, Pirker C, Hlavaty J, Petznek H, Hegedus B, Garay T, Mohr T, Sommergruber W, Grusch M, Berger W.

Oncotarget. 2013 Nov;4(11):1904-18.

46.

Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma.

Rózsás A, Berta J, Rojkó L, Horváth LZ, Keszthelyi M, Kenessey I, László V, Berger W, Grusch M, Hoda MA, Török S, Klepetko W, Rényi-Vámos F, Hegedűs B, Döme B, Tóvári J.

PLoS One. 2013 Oct 14;8(10):e77459. doi: 10.1371/journal.pone.0077459. eCollection 2013.

47.

Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

Heinzle C, Erdem Z, Paur J, Grasl-Kraupp B, Holzmann K, Grusch M, Berger W, Marian B.

Curr Pharm Des. 2014;20(17):2881-98. Review.

48.

Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells.

Saiko P, Graser G, Giessrigl B, Steinmann MT, Schuster H, Lackner A, Grusch M, Krupitza G, Jaeger W, Somepalli V, Golakoti T, Fritzer-Szekeres M, Szekeres T.

Invest New Drugs. 2013 Oct;31(5):1115-24. doi: 10.1007/s10637-013-0009-x. Epub 2013 Aug 14.

PMID:
23943154
49.

In vitro characterisation of the anti-intravasative properties of the marine product heteronemin.

Kopf S, Viola K, Atanasov AG, Jarukamjorn K, Rarova L, Kretschy N, Teichmann M, Vonach C, Saiko P, Giessrigl B, Huttary N, Raab I, Krieger S, Schumacher M, Diederich M, Strnad M, de Martin R, Szekeres T, Jäger W, Dirsch VM, Mikulits W, Grusch M, Dolznig H, Krupitza G.

Arch Toxicol. 2013 Oct;87(10):1851-61. doi: 10.1007/s00204-013-1045-1. Epub 2013 Mar 30.

PMID:
23543012
50.

Xanthohumol attenuates tumour cell-mediated breaching of the lymphendothelial barrier and prevents intravasation and metastasis.

Viola K, Kopf S, Rarova L, Jarukamjorn K, Kretschy N, Teichmann M, Vonach C, Atanasov AG, Giessrigl B, Huttary N, Raab I, Krieger S, Strnad M, de Martin R, Saiko P, Szekeres T, Knasmüller S, Dirsch VM, Jäger W, Grusch M, Dolznig H, Mikulits W, Krupitza G.

Arch Toxicol. 2013 Jul;87(7):1301-12. doi: 10.1007/s00204-013-1028-2. Epub 2013 Mar 17.

PMID:
23503627

Supplemental Content

Loading ...
Support Center